ArticleClinical rheumatology2026
Cancer-associated myositis: a single-centre 20-year experience.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignancy identified around the onset of idiopathic inflammatory myopathy (IIM) is referred to as cancer-associated myositis (CAM), but population-specific data remain relatively limited.
aimTo describe the prevalence, clinical features, and risk factors for CAM over a 20-year period in a single tertiary centre in Greece.
methodsA retrospective analysis was conducted on 113 IIM cases treated between 2001 and 2024 in our department, which is a referral centre for rheumatic disease in Central Greece. Medical records were evaluated for demographics, clinical characteristics, autoantibody profile, and comorbidities. CAM was defined as cases of myositis complicated by the onset or recurrence of cancer within 3 years before or after the diagnosis of myositis.
resultsCAM was identified in 25 (22.1%) patients. Older age and dermatomyositis subtype were associated with CAM. Anti-TIF1γ autoantibody confers significantly higher risk (OR 6.9, p < 0.001), while anti-Jo1 lowers risk (OR 0.13, p = 0.022). Gottron's papules and Holster sign were significantly associated with CAM. Raynaud's phenomenon, interstitial lung disease and the non-interstitial pneumonia pattern appeared protective. Hypothyroidism was less common, while myocardial infarction was more frequent in CAM. Breast, ovarian, and lung cancers were the most common malignancies identified. In most cases, malignancy was asymptomatic (85%) and was determined upon screening. Survival was significantly lower in CAM p < 0.001 with the survival rate dropping down to 45% at 31 months vs 95.9% in non-CAM. Median survival was 21 months in CAM cases (1-79 months).
conclusionCAM accounts for a substantial proportion of IIM cases. Anti-TIF1γ positivity, older age, absence of Raynaud's phenomenon, and absence of ILD may serve as clinical flags in our cohort. Comprehensive cancer screening, including GI endoscopy, remains vital in the initial assessment and follow-up, primarily upon relapses and lack of remission. Key Points • Population-based studies on cancer-associated myopathy have established a clear, strong link between idiopathic inflammatory myopathies (IIM) and malignancy, often termed cancer-associated myositis (CAM). • This study examines CAM prevalence, features, and risk factors over 20 years at a Greek tertiary center. • CAM was present in 22% of IIM patients, mostly asymptomatic (85%), identified through screening; breast, ovarian, and lung cancers were the common malignancies. • Akin to previous studies, anti-TIF1γ autoantibody confers a significantly higher risk, while anti-Jo1 lowers risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.